We Turn Cells Into AI Computers

Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee Flying Bee


AI for Genetic Circuit Designs
Example Applications for Cell Bioproduction

Latest News

Sharing of GeneNet story at Cytiva iHub! - March 2023

Thank you Cytiva for the invitation, we look forward to any future collaborations!

Learn More
Invited to share about our platform and panel discussion by the Innovate UK EDGE!

Genenet Technology was invited to share experience at the Trinity center, Cambridge.

Learn More
Invited to share about GeneNet's project at the Stevenage Bioscience Catalyst in GSK!

Thank you for having us in this event hosted by the Stevenage Bioscience Catalyst.

Learn More

2022 EUREKA GlobalStars Taiwan Call” kick-off meeting

September was an exciting month for us. Genenet joined the "2022 EUREKA GlobalStars Taiwan Call” kick-off meeting.

Learn More
New lab at the Stevenage Bioscience Catalyst in GSK!

Kicking off October, Genenet has been awarded space by Stevenage Bioscience Catalyst (SBC) in its Lab Hotel.

Learn More
Guest speaking invited by the Innovate UK EDGE

Thank you Innovate UK EDGE East of England and Stuart Coyle for having us in this event hosted by the Stevenage Bioscience Catalyst.

Learn More

About Us

Our patented technology can be applied to any field that needs genetic engineering (eg. medicine, synthetic biology and pharmaceutical industries). We plan to offer genetic circuit design service, consultation service and patent licensing to academic or industrial research units. Our product could worldwidely cover research units (including pharmaceutical companies and contract research organisation) with focus at high throughput drug discovery, CAR-T therapy and biomolecules detection.

There are many pain points in traditional biopharmaceutical research. For example, the high cost of research, time-consuming processes of drug development, and difficulties in treating complicated diseases. These problems not only harm the development of the biopharmaceutical industry, but also generate traumatic problems, such as COVID-19 pandemic, to our world. Genenet Technology provides a one-stop solution to address all these problems, in hope of taking the biopharmaceutical industry to the next level.

Our Technology

In synthetic biology, gene circuit is a synthetic gene which can fine-tune the control of expression of transcription factors in the manner of electronic circuits. However the current biocomputing method is still based on the logic gate genetic circuits (AND/OR/NOT) which can only accept simple Boolean inputs and outputs, thus the function of the gene circuit is limited to just classification of input.

Our technology integrates deep learning into the gene circuit design. Artificial neural network (ANN) has been emerging in recent years and is a fundamental part of deep learning. ANN allows regression or classification which makes quantification prediction of input becomes possible: We proposed a de novo biocomputing method, using genetic circuits to mimic ANNs and this unleashes the potential of the gene circuit design into the blue ocean applications that were impossible with gene circuit design using the simple logic gates. Our novel algorithm will be a revolutionary and ground-breaking technology which allows the gene circuit to be designed as if a deep neural network used by state-of-art computer scientists.

Our market

We will focus on three global markets, precision medicine, clinical detection and biotechnology. The global precision medicine market is expected to reach USD 100 billion by 2025 and our technology can be used, as an example, in well-developed fields such as CAR-T cell therapy for cancer (expecting CAGR:35.5%, USD 5 Billion by 2026).

Our technology offers quick and cost-effective high throughput screening results and this market is expected to exceed USD 20 billion by 2023. We can also help optimizing the production of different products (e.g. enzymes, metabolites, etc.) and this sector exceeded USD 400 billion in 2019.

Service Categories

We provides our client the best services to build customized genetic circuits which fit their need.

Sign-up for interests!

If you find our services satisfy your needs, starting the discussion is only one message away!


Dr. Leo Chi U SEAK

Chief Executive Officer (CEO)
  • PhD, University of Cambridge
  • 5 iGEM Gold medals, iGEM judge 2020-2021
  • Expertise:
    • AI, Neuroscience
    • Business Development

    Dr. Louis Ming Tsung Wu

  • Postdoc, Imperial College London
  • Ex–Postdoc, University of Cambridge
  • Expertise:
    • Bioinformatics, Epigenetic regulation
    • Business Development

    Dr. Marco Chi Yeung Ip

    Lead Scientist - Cell Culture Development
  • PhD, University of Cambridge
  • MSc, Osaka University
  • Expertise:
    • Cancer Signaling, Cell Engineering

    Owen Lok In Lo

  • PhD, The University of Edinburgh
  • Expertise:
    • Pharmacology
    • Finance and Marketing

    Godwin Long In Lo

    Scientific Researcher
  • MSc, University of Glasgow
  • Expertise:
    • Synthetic Biology, Cell Engineering

    Haydn Chon In Cheong

    Machine learning engineer
  • MSc, The University of Edinburgh
  • Expertise:
    • AI, Bioinformatics



    SG1 2FX

    Your message has been sent. Thank you!